Sather Financial Group Inc Boosts Position in Johnson & Johnson $JNJ

Sather Financial Group Inc increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 108.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,756 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. Sather Financial Group Inc’s holdings in Johnson & Johnson were worth $879,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $35,000. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $48,000. Finally, von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ opened at $190.88 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a 50-day moving average price of $178.88 and a 200 day moving average price of $163.97. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The company has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Bank of America lifted their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Citigroup lifted their price target on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Morgan Stanley lifted their price target on Johnson & Johnson from $176.00 to $178.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.